v3.26.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (49,013) $ (64,918)
Adjustments required to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 3,194 463
Convertible loans induced conversion expenses 4,304
Capital gain, net (1,580)
Loss (gain) from deconsolidation of OBI, Korea and Belgium subsidiaries in 2024 (Octomera in 2023) (4,480) 5,343
Share in loss of associated companies, net 8 734
Depreciation and amortization expenses 2,086 1,560
Credit loss on convertible loan receivable 2,688
Credit loss net related to OBI, Korea and Belgium subsidiaries 2,049
Impairment of investment (see note 2) 699
Impairment expenses (see note 2) 18,338
Effect of exchange differences on inter-company balances 2,447 227
Net changes in operating leases 1,588 (50)
Change in Contingent consideration (4,643)
Interest expense accrued on loans and convertible loans 1,538 1,508
Loss from extinguishment in connection with convertible loan restructuring 5,422 283
Changes in operating assets and liabilities:    
Accounts receivable 130 30,060
Prepaid expenses, other accounts receivable 2,262 432
Inventory 34 (389)
Other assets 43 13
Related parties, net (2) (439)
Accounts payable (1,279) 5,516
Accrued expenses and other payable (820) 1,013
Employee and related payables 1,300 411
Deferred taxes, net (2) 9
Net cash used in operating activities (17,076) (14,837)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Decrease in loan to associate entities 55
Purchase of property, plants and equipment (263) (2,096)
Investment in associated company (660)
Cash acquired from acquisition of Octomera (see note 3) 139
Impact to cash resulting from deconsolidation of OBI, Korea and Belgium subsidiaries (see note 20) (11)
Impact to cash resulting from deconsolidation (973)
Investment in long-term deposits 500 (33)
Net cash used in investing activities 365 (3,707)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of shares due to exercise of options and warrants (net of transaction costs) 2,556 5,283
Proceeds from issuance of convertible loans 75 5,735
Proceeds from transaction with redeemable non-controlling interest that do not result in a loss of control 5,000
Repayment of convertible loans and convertible bonds (3,000)
Repayment of short and long-term debt (226) (35)
Proceeds from issuance of loans payable 6,060 635
Grant received in respect of third party 774
Receipt from Germfree (see note 13f) 6,720
Net cash provided by financing activities 15,959 13,618
NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH (752) (4,926)
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS (40) 36
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF YEAR 1,479 6,369
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF YEAR 687 1,479
SUPPLEMENTAL NON-CASH FINANCING AND INVESTING ACTIVITIES    
Right-of-use assets obtained in exchange for new finance lease liabilities 16,007
Right-of-use assets obtained in exchange for new operation lease liabilities 405 752
Increase (decrease) in accounts payable related to purchase of property, plant and equipment 14
Extinguishment in connection with convertible loan restructuring 5,281 287
CASH PAID DURING THE YEAR FOR:    
Interest $ 4 $ 785